Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase Deficiency
Eduard J. van Beers(Utrecht University), Kevin H.M. Kuo(University Health Network), Vanessa Beynon(Agios Pharmaceuticals (United States)), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), John B. Porter(Royal London Hospital), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Hanny Al‐Samkari(Harvard University), Emily Xu, Bryan McGee(Agios Pharmaceuticals (United States)), Malia P. Judge(Agios Pharmaceuticals (United States)), Andreas Glenthoej(Herlev Hospital), Rachael F. Grace(Dana-Farber/Boston Children's Cancer and Blood Disorders Center)
Cited by 3
Related Papers
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309